Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

Core Insights - Profound Medical Corp. has regained exclusive distribution rights for the TULSA-PRO system in Canada from Knight Therapeutics Inc. for a one-time payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian net sales for 15 years [3][4][5] Company Overview - Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [6][8] - The TULSA Procedure™ is designed to ablate prostate tissue in men suffering from prostate cancer and benign prostatic hyperplasia (BPH) [2][7] Technology and Procedure - The TULSA Procedure utilizes real-time MRI guidance and robotically guided ultrasound to precisely ablate targeted prostate tissue without harming surrounding structures [4][7] - The TULSA-PRO system is the only AI-powered, MRI-guided robotic system for prostate treatment, allowing for unmatched precision in therapy [4][7] - The procedure is incision-free, radiation-free, and typically performed in a single session, with most patients reporting quick recovery [7][8] Market Potential - Currently, there is only one Canadian site offering the TULSA Procedure, but there are plans to expand this through additional sites using a concierge service model [4][5] - The company aims to leverage results from the Level I prostate cancer CAPTAIN trial to support applications for health insurance coverage in Canada, which could significantly increase the market opportunity for the TULSA Procedure [4][5] Strategic Initiatives - Profound is deploying its own direct sales team in North America while partnering with strategic distribution partners to enhance business potential globally [5]